CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting

CARsgen Therapeutics Holdings Ltd a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2022 American Society of Hematology (the "ASH") Annual Meeting, the Company presented a poster with the results of the phase II LUMMICAR STUDY 1 clinical trial of zevorcabtagene autoleucel ("zevor-cel", R&D code: CT053, an autologous CAR T-cell product candidate against BCMA) in Chinese patients with relapsed/refractory multiple myeloma (R/R MM). This poster reports for the first time the pivotal phase II safety and efficacy data of LUMMICAR STUDY 1.Phase ? Study of Fully Human BCMA-Targeted CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma Zevor-cel, a fully human autologous CAR T-cell product targeting B-cell maturation antigen (BCMA), is being evaluated for patients with R/R MM in LUMMICAR STUDY 1 (NCT03975907), an ongoing phase I/II clinical trial in China. Results for the 14 subjects treated in phase I of LUMMICAR STUDY 1 showed a well-tolerated safety profile, plus deep and durable responses with an objective response rate (ORR) of 100% and a complete response/stringent complete response (CR/sCR) rate of 78.6%. A total of 102 patients with R/R MM were treated with zevor-cel at the dose of 150

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!